Abha Amin, MD
Ophthalmology · Valhalla, NYNPI 1023105608
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Bausch & Lomb Americas Inc. accounts for 68.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $16,822 and has fallen 89.8% since, to $1,714 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $180.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$21K
- Alcon$2K
- AbbVie$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Glaukos Corporation$1K
- Thea Pharma Inc.$975
- plus $3K from 19 others
What the payments were for
- Consulting fees$9,57731%
- Speaking & faculty fees$8,05026%
- Travel & lodging$1,7676%
- Food & beverage$11,75438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 53 | $21,342 |
| Alcon | 20 | $2,138 |
| AbbVie(2 entities) | 19 | $1,239 |
| Johnson & Johnson Surgical Vision, Inc. | 30 | $1,172 |
| Glaukos Corporation | 13 | $1,125 |
| Thea Pharma Inc. | 1 | $975 |
| NEW World Medical,inc. | 4 | $938 |
| Carl Zeiss Meditec USA, Inc. | 4 | $383 |
| Carl Zeiss Meditec, Inc. | 5 | $325 |
| Tarsus Pharmaceuticals, Inc. | 3 | $311 |
| Amgen | 3 | $258 |
| Harrow Eye, LLC | 3 | $174 |
| Sight Sciences, Inc. | 1 | $147 |
| Ivantis, Inc | 2 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| Aerie Pharmaceuticals, Inc. | 1 | $101 |
| Rxsight Inc | 1 | $63 |
| Apellis Pharmaceuticals, Inc. | 1 | $44 |
| Biotissue Holdings Inc. | 2 | $32 |
| Nova Eye, Inc. | 1 | $27 |
| Novartis | 1 | $25 |
| Dompe US, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Iridex Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$23,114
- IC-8 Apthera IOL$6,546
- enVista Aspire IOL$3,750
- TOTALVISC$2,450
- IYUZEH$975
- NGENUITY$651
- Ahmed Glaucoma Valve$538
- Kahook Dual Blade$538
- Streamline Surgical System$414
- iDoseTR$304
- TEPEZZA$249
- XEN GLAUCOMA TREATMENT SYSTEM$235
- LUMIGAN$227
- XIIDRA$153
- MIEBO$153
- STELLARIS$149
- OMNI(R) SURGICAL SYSTEM (US)$147
- Clareon$145
- AcrySof$143
- TORIC$143
How this compares
$31,148 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 107 | $5,140 |
| ProlensaBromfenac Sodium | 14 | $4,668 |
| Bromfenac Sodium | 13 | $2,655 |
| Ketorolac Tromethamine | 76 | $2,408 |
| MoxifloxacinMoxifloxacin Hcl | 78 | $1,843 |
| Latanoprost | 103 | $738 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $641 |
| ErythromycinErythromycin Base | 29 | $328 |
| Brimonidine Tartrate | 29 | $301 |
| Dorzolamide Hcl | 13 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $15 | $4,66814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Valhalla
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.